Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00635024 · OUTCOME

Progression-free Survival (PFS)

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma · Source last updated 2017-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
up to 2 years

What was measured

PFS was defined as the time from registration to progression or death due to any cause. Progression was defined as any one or more of the following: An increase of 25% from lowest confirmed response in: * Serum M-component (absolute increase \>= 0.5g/dl) * Urine M-component (absolute increase \>= 200mg/24hour * Difference between involved and uninvolved Free Light Chain levels (absolute increase \>= 10mg/dl) * Bone marrow plasma cell percentage (absolute increase of \>=10%) * Definite development of new bone lesion or soft tissue plasmacytomas

Groups in this outcome

Anti-thymocyte Globulin/Melphalan

Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Anti-thymocyte Globulin/Melphalan1

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Anti-thymocyte Globulin/Melphalan2.9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2.9
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
PFS was defined as the time from registration to progression or death due to any cause. Progression was defined as any one or more of the following: An increase of 25% from lowest confirmed response in: * Serum M-component (absolute increase \>= 0.5g/dl) * Urine M-component (absolute increase \>= 200mg/24hour * Difference between involved and uninvolved Free Light Chain levels (absolute increase \>= 10mg/dl) * Bone marrow plasma cell percentage (absolute increase of \>=10%) * Definite development of new bone lesion or soft tissue plasmacytomas
dispersion Type
95% Confidence Interval
groups
  1. description
    Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)
    id
    OG000
    title
    Anti-thymocyte Globulin/Melphalan
param Type
MEDIAN
reporting Status
POSTED
time Frame
up to 2 years
title
Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice